基于临床及实验研究观察针灸在非小细胞肺癌治疗中的作用
|
摘要
肺癌发病率、死亡率高,发现时多为晚期。传统治疗包括手术、放疗、化疗等局限性日渐凸显,分子靶向药物作用不确切。多学科综合治疗模式是肺癌治疗的方向。中药治疗肿瘤已体现出“带瘤生存”的优势,但近年来中药治疗肺癌疗效没有大的突破。为进一步提高疗效,探讨中医综合治疗模式,有必要进行针灸治疗肿瘤的相关研究。针灸具有良性、双向性、整体性的治疗特点,临床观察发现针灸对肿瘤的疗效,尤其在改善症状、减轻放化疗副反应、增加放化疗效果方面作用确切,且副反应小、费用低廉。通过文献回顾发现目前的研究存在诸多问题,如不少文献无对照；部分国内文献缺乏客观的诊断标准；临床研究方法及治疗方案不规范；样本量少；疗效评价标准差异大等等,造成结果可信度较低。本研究拟通过客观科学的临床及实验研究,观察针灸在NSCLC治疗中的意义,并探讨其部分作用的机制。
1针灸在NSCLC临床治疗中的作用
[目的]通过前瞻、对照的临床研究,观察并分析针灸对中晚期NSCLC患者的疗效指标、安全性指标的影响,探讨针灸对NSCLC肺癌临床症状、生存质量、体力状况评分、化疗副反应、理化指标等方面的作用。
[方法]本研究病例来自广州中医药大学第一附属医院、广东省中医院、广州市中医医院、佛山市中医院等四家医院在2008年9月-2011年3月期间Ⅲ-Ⅳ期NSCLC住院及门诊患者,共205例。根据病情及患者意愿进行分组治疗。其中中药治疗组48例,中药针灸治疗组61例,中药化疗组45例,针药化疗组51例。
中药治疗组采用辨病与辨证相结合的治疗方法。辨病治疗包括口服清金得生片和参一胶囊；辨证分型治疗按肺郁痰瘀、脾虚痰湿、阴虚痰热、气阴两虚四种分型加用汤剂治疗。21天为一疗程,共两疗程。中药针灸治疗组为针刺及敷贴治疗+中药治疗,穴位处方为肺俞、膏肓、膈俞、胆俞、足三里(均双侧)。治疗21天为一疗程,共两疗程,采取疗程前5天针灸治疗,后16天穴位敷贴治疗的方法；中药化疗组为化疗+中药治疗,化疗方案为含铂类方案,可选用NP/GP/DP方案或选用多西他赛或培美曲塞治疗。每21天重复,共2个周期；针药化疗组为针刺及敷贴治疗+化疗+中药治疗,同时采用上述三组的治疗。主要疗效指标是症状改善、体力状况评分、生存质量,化疗副反应改善、肿瘤缓解等。
[结果]在肿瘤缓解上：有效率分别为中药组4.17%,中药针灸组4.92%,中药化疗组24.44%,针药化疗组27.45%；稳定率分别为中药组56.25%,中药针灸组59.02%,中药化疗组75.56%,针药化疗组86.27%。中药化疗组与针药化疗组的肿瘤缓解情况均都比中药组或中药针灸组更好,有统计学意义；针药化疗组与其他三组的肿瘤稳定率比较,有显著性差异。
在临床症状评分方面：各组治疗前后自身比较均有明显的改善(F=8.851,P=0.000<0.05)；针药化疗组疗效较其他三组更好；中药化疗组次之,与中药组及中药针灸组比较有统计学意义。
在PS评分上：四组治疗前后自身比较,均有不同程度的改善,其中针药化疗组较其他三组改善更明显(P<0.05),中药化疗组次之,与中药组及中药针灸组比较有统计学意义。
在生存质量评分方面：各组生存质量积分治疗后比较：中药针灸组、中药组治疗后较治疗前自身对照均有明显升高,中药针灸组较中药组更高,但两者之间没有统计学意义；中药化疗组及针药化疗组治疗后对比治疗前评分下降,中药化疗组比针药化疗组下降更明显,但无显著性差异；中药针灸组在情绪状况领域、功能状况领域以及肺癌关注情况方面较中药组改善更明显,有统计学意义。另外,针灸对不同证型的患者的生存质量评分均有提高,以脾虚痰湿组最为明显,有统计学意义。
在对化疗副反应的作用方面：除口腔炎/咽炎对比治疗前无显著性差异外,其他各项症状体征得分均有上升,有统计学意义。中药化疗组在恶心呕吐、腹泻及便秘等症状上较针药化疗组得分升高更明显；针药化疗组在瘙痒症状上较中药化疗组得分升高更明显。
在血象方面：中药化疗组、针药化疗组PLT、PLT下降较中药针灸组或中药组明显,有统计学意义；中药化疗组PLT、PLT下降较针药化疗组更明显,有统计学意义；中药针灸组的WBC较中药组升高更明显。
在肿瘤标志物方面：四组CEA、CA125、CA199治疗后较治疗前自身对比,均有显著性下降；中药化疗组、针药化疗组CEA、CA199均较中药针灸组和中药组下降明显,有统计学意义；针药化疗组能使CA125下降更多,与其他三组有显著性差异。
在治疗安全性方面,并未发现有因针灸而导致的心肝肾功能的损害,小部分的患者出现皮下出血、轻度疼痛等情况,较多见的副反应为穴位敷贴部位皮肤潮红、瘙痒等。经对症处理后症状可减退,可以继续治疗。整体而言,针灸治疗具有较好的安全性。
[结论]在中药基础上配合针灸治疗中晚期NSCLC,较单用中药治疗,在稳定血象、改善生存质量,尤其是情绪状况领域、功能状况领域以及肺癌关注情况等方面有更大的优势；化疗、中药联合针灸治疗较化疗配合中药治疗在改善肺癌症状、降低PS、稳定肿瘤、减少化疗副反应、减少WBC下降等方面效果更好,并能使CA125下降更多；根据肿瘤稳定率、症状改善情况、肿瘤相关指标等综合评价,可以判断针灸对化疗具有一定的增效作用；综合评价症状改善情况、PS评分、血象、化疗副反应等方面,判断针灸对化疗具有一定的减毒作用。另外,针灸对不同证型的肺癌患者生存质量均有较好的改善,而对脾虚痰湿型患者效果最明显。
根据肿瘤稳定率、症状改善、PS评分改善、肿瘤指标降低等方面综合评价,包括中药、针灸、化疗等方面的中医综合治疗,在中晚期非小细胞肺癌治疗上较单用中药或中药+针灸或中药+化疗具有更大的优势。
针灸在中晚期肺癌治疗中的作用明显,无明显副反应,值得临床推荐。
2针灸治疗荷Lewis肺癌小鼠的实验研究
[目的]通过动物实验,建立荷Lewis肺癌小鼠模型,观察针灸对荷Lewis肺癌小鼠的治疗作用及其部分作用机制。
[方法]60只小鼠随机分为4组,每组15只,分别为荷瘤空白组,荷瘤针灸组,荷瘤化疗组,荷瘤化疗针灸组。首先建立Lewis肺癌动物模型。先将液氮冻存的小鼠Lewis肺癌小鼠细胞复苏后,先接种于4只C57BL/6小鼠右腋窝皮下,制备传代荷瘤鼠。传3代后处死小鼠,在无菌条件下剥取荷瘤小鼠瘤块,制备成5×106/ml肿瘤细胞悬液。每只小鼠右侧腋窝皮下接种0.2ml肿瘤细胞悬液。接种后第二天开始治疗,荷瘤化疗组参照张素胤用量(1mg/kg),以DDP溶液0.1ml/20g每日腹腔注射1次,连续10天；荷瘤针灸组取肺俞(双侧交替)、足三里(双侧交替),用30号毫针(0.5寸),常规消毒后直刺0.2-0.3寸,留针5分钟,每日一次,早上10时执行,连续10天；荷瘤化疗针灸组采用荷瘤化疗组及荷瘤针灸组的治疗。
[结果]连续治疗10天后存活小鼠空白组15只,针灸组14只,化疗组12只,针灸化疗组12只。治疗期间死亡率化疗组、针灸化疗组较空白组、针灸组更高,有统计学意义；化疗组较针灸化疗组更高,有统计学意义。
瘤体重量比较：空白组为3.25±0.26g,针灸组为2.84±0.41g,化疗组为2.37±0.47g,针灸化疗组为2.03±0.27g；针灸组、化疗组、针灸化疗组抑瘤率分别为12.58%、27.07%、37.41%；针灸组瘤重与化疗组、针灸化疗组比较,差异均有统计学意义；化疗组与针灸化疗组比较,差异有统计学意义。各组去瘤体重比较：以针灸组最重,其次为空白组、针灸化疗组,化疗组最轻,但四组间差异无统计学意义。
免疫器官重量比较：脾重分别为空白组0.20±0.03g,针灸组0.27±0.06g,化疗组0.18±0.03g,针灸化疗组0.26±0.05g；针灸组与空白组比较,有统计学意义；针灸化疗组与空白组、化疗组比较,有统计学意义。胸腺重量针灸组最重,但四组间无显著性差异。
细胞因子水平比较：血清TNF-α,分别是空白组2.00±0.24ng/m1,针灸组1.96±0.45ng/ml,化疗组2.38±0.28ng/ml,针灸化疗组2.31±0.30ng/ml；TNF-α水平以化疗组最高,其次为针灸化疗组；化疗组、针灸化疗组分别与空白组、针灸组比较均有显著性差异；化疗组和针灸化疗组之间,空白组和中药针灸组之间,均无显著性差异。血清IL-6,分别为126.13±22.85pg/ml,针灸组84.48±15.03pg/ml,化疗组110.78±15.25pg/ml,针灸化疗组90.95±14.72pg/ml；空白组最高,较其他三组有显著性差异；针灸组最低,其次为针灸化疗组,针灸组与化疗组之间有显著性差异,针灸组和针灸化疗组之间无显著性差异。
[结论]针灸治疗对荷瘤小鼠具有一定的抑瘤作用,其作用虽不及化疗明显,但如针灸能联合化疗则较单纯针灸或化疗更能抑制肿瘤进展。该结果与本研究的临床研究结果基本相符,进一步体现中西医综合治疗肿瘤的优势。
针灸可增加免疫器官(脾)的重量,减轻肿瘤及化疗对免疫功能的损害,具有一定的免疫保护作用,可能是针灸抗肿瘤的机制之一。
TNF-α与IL-6水平均可作为监测肺癌病程进展、治疗效果以及疾病预后的辅助指标,同时也与肿瘤导致的虚证密切相关。中医认为,肿瘤产生的基础是正虚,正虚与肿瘤形成及其病机演变、预后等皆有密切关系,而中晚期肺癌多因虚致病,因病致虚,辨证多为虚中夹实或虚实夹杂,肺癌化疗后尤多见脾肾亏虚。因此,扶正补虚是中晚期肺癌的重要治疗原则。针灸具有扶正培本的作用,能明显改善虚证。本研究表明,针灸治疗具有显著降低血清TNF-α和IL-6浓度的作用,提示针灸可能是通过改善肺癌的虚证而达到治疗目的,该作用可能是针灸治疗肺癌产生疗效的重要因素之一。
此外,针灸安全性较好,未见明显副作用。
The incidence rate and the death rate of the lung cancer is very high, most of the patients are on the advanced stage when they are diagnosed. The conventional therapy of lung cancer including the operations、radiotherapy and the chemotherapy has its limit, the effect of the targeted drugs is not certain. The mode of combined therapy is the trend of the treatment of lung cancer. TCM has showed up the superiority of "living with the tumor", but the curative effect are similar in recent years. The acupuncture and moxibustion has the characteristic of innocuousness、ambidirectional dominance and entirety, so it works in the treatment of lung cancer, especially improving symptoms、easing the side effects and raising the curative effect of the radiotherapy and the chemotherapy, and it has little side effect and it charges little. There are many problem in the study and research of the acupuncture and moxibustion, as some of them have no control groups, some have no standard diagnostic criteria、treatment perscription and the evaluation criterion, some have small sample size, and it made the result not confident.This article is about the analysis of curative effect of acupuncture and moxibustion including quality of life、symtoms、side effects of chemotherapy etc in nonsmall-cell lung cance (NSCLC) based on the perspective and control study;and trys to analyse the impact on the of mouse with lung cancer of acupuncture and moxibustion.
1 The analysis of curative effect of acupuncture and moxibustion in NSCLC based on the clinical research.
OBJECTIVE:Observe the curative effect of acupuncture and moxibustion including quality of life、symtoms、side effects of chemotherapy etc in nonsmall-cell lung cance (NSCLC) based on the perspective and control study.
METHODS:From Sep,2008 to Mar,2011,205 patients, with NSCLC in stageⅢ-Ⅳ, were recruited in four hospitals including The 1st affiliated hospital of Guangzhou University of TCM, The 2nd affiliated hospital of Guangzhou University of TCM, Guangzhou Hospital of TCM and Foshan Hospital of TCM.48 cases in group TCM(group T),61 cases in group integrated acupunture with TCM (group A+T),45 cases in group integrated chemotherapy with TCM (group C+T), and 51 cases in group integrated acupunture, chemotherapy with TCM(group A+C+T).
Project for group TCM:with combination of syndrome differen-tiation and disease differentiation, Qingjingdesheng tablets and Shenyi capsules were used according to disease differentiation, and different decoctions were determined from four patterns:phlegmatic stagnation due to passive congestion of lungs (FYTY), phlegmatic hygrosis due to spleen asthenia(PXTS), yin-deficiency and phlegmopyrexia(YXTR) and deficiency ofboth qi and yin(QYLX) according to syndrome diffentiation, and the period of treatment was two courses,21days per course. Project for group integrated acupunture with TCM:the treatment of TCM is the same as group TCM. both Lung Shu, Vital Organs, Diaphragm Shu, Gallbladder Shu and Foot Three Li were chosen in the acupunture therapy, the period of treatment was two courses,21days per course. The first 5 days needling and the last 16 days point application. Project for group integrated chemotherapy with TCM:Platinum-based chemotherapy were used besides the treatment of TCM, either NP/GP/DP regimen or Docetaxel/pemetrexed was adopted, and were repeated every 21days, two times. Project for group integrated acupunture, chemotherapy with TCM:the treatment is the same as the last three groups. The primary points was symptoms improvement, survival, quality of life, side effect of chemotherapy improvement, tumor response rate, ECOG.
RESULTS:Tumor response rate(CR+PR) were 4.17% of group TCM,4.92% of group A+T,24.44% of group C+T,27.45% of group A+C+T;The disease control rate were 56.25%of group TCM,59.02% of group group A+T,75.56% of group of group C+T,86.27% of group A+C+T. There were statistical significance between group T/ A+T with group C+T/ A+C+T; there were statistical significance between group A+C+T and the other groups in the disease control rate.
Symptoms scales changes after treatment of four groups compared:there were statistical significance between group A+C+T and the other groups, there were statistical significance between group C+T and the group T/ A+T.
PS scales decrease after treatment of four groups compared:there were statistical significance between group A+C+T and the other groups, there were statistical significance between group C+T and the group T/ A+T.
The quality of life changes after treatment of four groups compared: group A+T and group T inproved after the treatment, but group C+T and group A+C+T decreased after the treatment. There were statistical significance between the group A+T and the group T in the emotional condition funtional condition and lung cancer information. And acupunture works for all types of syndrome, especially for the patients who have got phlegmatic hygrosis dueto spleen asthenia(PXTS).
Most of the side effect scales worsened after the treatment of group C+T and group A+C+T. Refers to the symtoms like nausea and vomitting、diarrhoea constipation and pruritus, there were statistical significance between group C+T and group A+C+T.
WBC and PLT scales changed after treatment of four groups compared: there were statistical significance between group T/ A+T and other two groups, there were statistical significance between group A+C+T and group C+T, there were statistical significance between group A+T and the group T.
CEA、CA125、CA199 decreased after the treatment of four groups;CEA、CA199 in group C+T、group A+C+T decreased more than group A+T and group T. Group A+C+T was the lowest, and there were statistical significance between group A+C+T and the other three groups.
The heart function、Hepatic function and renal function of the patients has not getten worse after the acupumture therapy. Some patients got subcutaneous hemorrhage、pain after the treatment. The common side effects were erubescence and pruritus. The side effects could be cured, and so the acupumture therapy is safe.
CONCLUSI ONS:The treatment integrated acupumture with TCM is better at stabilizing hemogram、improving the quality of life such as emotional condition functional condition and lung cancer imformation than TCM. The treatment integrated chemotherapy、acupumture and TCM is better at improving the sympton、decreasing PS、stabilizing hemogram、increasing the disease control rate、decreasing the side effect of chemotherapy and decreasing CA125 than the treatment integrated chemotherapy and TCM. According to the disease control rate、symptoms improvement tumor markers, acupumture can elevate the effect of chemotherapy. According to the symptoms improvement PS decrease、hemogram、side effect of chemotherapy, acupumture can degrade the toxicity of chemotherapy. And acupunture works for all types of syndrome, especially for the patients who have got phlegmatic hygrosis dueto spleen asthenia(PXTS).
According to the disease control rate、symptoms improvement、PS decrease and tumor markers, the treatment integrated chemotherapy、acupumture with TCM is the best way to cure NSCLC. And acupumture is very safe.
2 The Experimental Research of acupumture in Treatment of Lewis Lung Cancer(LLC) Mice
OBJECTIVE:To analyse the effect of acupuncture and moxibustion on the mice with lung cancer.
METHODS:60 C57BL/6 mice were randomly divided into four groups, there were15 mice each group, and four groups as follows:LLC blank (group A), LLC acupumture (group B), LLC chemotherapy(group C) and LLC acupumture and chemotherapy(group D).Step 1:After awaking LLC cells to be frozen by liguid nitrogen, four C57BL/6 mice'right axilla subcutaneous part were inoculated by LLC cells 2.5×105, for establishing transfer of culture LLC mice. The mice were killed after transfer to three generation, and tumor was taken in sterile to make tumor cell suspension which concentration was 5×106/ml. Every mouse'right axilla subcutaneous part was inoculated by 0.2ml tumor cell suspension. On the second day Post inoculation, treatment began. In group B, Both Lung Shu, Foot Three Li were chosen in the acupunture therapy, and every day for 10 days.Group C were administrated intraperitoneal cisplatin by 0. lml/20g every day for 10 days. Group D took the same treatment with group B and group C.
RESULTS:After continues treatment for ten days, survival mice number of group A, B, C and D were 15,14,12 and 12 respectively。The death rate of group C and D is higher than group A and B, and group C is higher than group D. Weight of tumor of group A, B, C and D were 3.25±0.26g,2.84±0.41g,2.37±0.47g and 2.03±0.27g respectively;There were statistical significance between group B and group C or D; there were statistical significance between group C and D. Suppress tumor rate of group B、C and D were 12.58%、27.07%、37.41% respectively. Body weight except tumor of group compared:group B is the heavest, but there was no statistical significance between groups.
Weight of spleen of group A, B, C and D were 0.20±0.03g,0.27±0.06g, 0.18±0.03g and 0.26±0.05g respectively;Weight of thymus gland of group A, B, C and D were 0.055±0.016g,0.036±0.015g,0.031±0.008g and 0.045±0.012g respectively;there were statistical significance between group A and group B; there were statistical significance between group D and group A or C. Weight of thymus gland compared:group B is the heavies, but there was no statistical significance between groups.
Serum TNF-αlevel of group A, B, C and D were 2.00±0.24ng/ml,1.96±0.45ng/ml,2.38±0.28ng/ml,2.31±0.30ng/ml respectively;there were statistical significance between group C/D and group A/B, but there was no statistical significance between group A and B or C and D. Serum IL-6 levels of group A, B, C and D were 126.13±22.85pg/ml,84.48±15.03pg/ml, 110.78±15.25pg/ml,90.95±14.72pg/ml respectively;there were statistical significance between group A and the other groups;there were statistical significance between group B and C.
CONCLUSIONS:The treatment of acupumture could suppress tumor growth of LLC mice, which was weaker than chemotherapy, but acupumture integrated with chemotherapy would be better than acupumture only or chemotherapy only.
The treatment of acupumture could increase the weight of LLC mice spleen to some extent, and enhance immune function of animal body to some extent.
TNF-αand IL-6 is the index that could reflect the lung cancer aggravation therapeutic efficacy and the prognosis, and correlates to the deficient syndrome. Acupumture could decrease serum TNF-αand IL-6 levels significantly, which may be one of important reasons for treating the lung cancer.
1针灸在NSCLC临床治疗中的作用
[目的]通过前瞻、对照的临床研究,观察并分析针灸对中晚期NSCLC患者的疗效指标、安全性指标的影响,探讨针灸对NSCLC肺癌临床症状、生存质量、体力状况评分、化疗副反应、理化指标等方面的作用。
[方法]本研究病例来自广州中医药大学第一附属医院、广东省中医院、广州市中医医院、佛山市中医院等四家医院在2008年9月-2011年3月期间Ⅲ-Ⅳ期NSCLC住院及门诊患者,共205例。根据病情及患者意愿进行分组治疗。其中中药治疗组48例,中药针灸治疗组61例,中药化疗组45例,针药化疗组51例。
中药治疗组采用辨病与辨证相结合的治疗方法。辨病治疗包括口服清金得生片和参一胶囊；辨证分型治疗按肺郁痰瘀、脾虚痰湿、阴虚痰热、气阴两虚四种分型加用汤剂治疗。21天为一疗程,共两疗程。中药针灸治疗组为针刺及敷贴治疗+中药治疗,穴位处方为肺俞、膏肓、膈俞、胆俞、足三里(均双侧)。治疗21天为一疗程,共两疗程,采取疗程前5天针灸治疗,后16天穴位敷贴治疗的方法；中药化疗组为化疗+中药治疗,化疗方案为含铂类方案,可选用NP/GP/DP方案或选用多西他赛或培美曲塞治疗。每21天重复,共2个周期；针药化疗组为针刺及敷贴治疗+化疗+中药治疗,同时采用上述三组的治疗。主要疗效指标是症状改善、体力状况评分、生存质量,化疗副反应改善、肿瘤缓解等。
[结果]在肿瘤缓解上：有效率分别为中药组4.17%,中药针灸组4.92%,中药化疗组24.44%,针药化疗组27.45%；稳定率分别为中药组56.25%,中药针灸组59.02%,中药化疗组75.56%,针药化疗组86.27%。中药化疗组与针药化疗组的肿瘤缓解情况均都比中药组或中药针灸组更好,有统计学意义；针药化疗组与其他三组的肿瘤稳定率比较,有显著性差异。
在临床症状评分方面：各组治疗前后自身比较均有明显的改善(F=8.851,P=0.000<0.05)；针药化疗组疗效较其他三组更好；中药化疗组次之,与中药组及中药针灸组比较有统计学意义。
在PS评分上：四组治疗前后自身比较,均有不同程度的改善,其中针药化疗组较其他三组改善更明显(P<0.05),中药化疗组次之,与中药组及中药针灸组比较有统计学意义。
在生存质量评分方面：各组生存质量积分治疗后比较：中药针灸组、中药组治疗后较治疗前自身对照均有明显升高,中药针灸组较中药组更高,但两者之间没有统计学意义；中药化疗组及针药化疗组治疗后对比治疗前评分下降,中药化疗组比针药化疗组下降更明显,但无显著性差异；中药针灸组在情绪状况领域、功能状况领域以及肺癌关注情况方面较中药组改善更明显,有统计学意义。另外,针灸对不同证型的患者的生存质量评分均有提高,以脾虚痰湿组最为明显,有统计学意义。
在对化疗副反应的作用方面：除口腔炎/咽炎对比治疗前无显著性差异外,其他各项症状体征得分均有上升,有统计学意义。中药化疗组在恶心呕吐、腹泻及便秘等症状上较针药化疗组得分升高更明显；针药化疗组在瘙痒症状上较中药化疗组得分升高更明显。
在血象方面：中药化疗组、针药化疗组PLT、PLT下降较中药针灸组或中药组明显,有统计学意义；中药化疗组PLT、PLT下降较针药化疗组更明显,有统计学意义；中药针灸组的WBC较中药组升高更明显。
在肿瘤标志物方面：四组CEA、CA125、CA199治疗后较治疗前自身对比,均有显著性下降；中药化疗组、针药化疗组CEA、CA199均较中药针灸组和中药组下降明显,有统计学意义；针药化疗组能使CA125下降更多,与其他三组有显著性差异。
在治疗安全性方面,并未发现有因针灸而导致的心肝肾功能的损害,小部分的患者出现皮下出血、轻度疼痛等情况,较多见的副反应为穴位敷贴部位皮肤潮红、瘙痒等。经对症处理后症状可减退,可以继续治疗。整体而言,针灸治疗具有较好的安全性。
[结论]在中药基础上配合针灸治疗中晚期NSCLC,较单用中药治疗,在稳定血象、改善生存质量,尤其是情绪状况领域、功能状况领域以及肺癌关注情况等方面有更大的优势；化疗、中药联合针灸治疗较化疗配合中药治疗在改善肺癌症状、降低PS、稳定肿瘤、减少化疗副反应、减少WBC下降等方面效果更好,并能使CA125下降更多；根据肿瘤稳定率、症状改善情况、肿瘤相关指标等综合评价,可以判断针灸对化疗具有一定的增效作用；综合评价症状改善情况、PS评分、血象、化疗副反应等方面,判断针灸对化疗具有一定的减毒作用。另外,针灸对不同证型的肺癌患者生存质量均有较好的改善,而对脾虚痰湿型患者效果最明显。
根据肿瘤稳定率、症状改善、PS评分改善、肿瘤指标降低等方面综合评价,包括中药、针灸、化疗等方面的中医综合治疗,在中晚期非小细胞肺癌治疗上较单用中药或中药+针灸或中药+化疗具有更大的优势。
针灸在中晚期肺癌治疗中的作用明显,无明显副反应,值得临床推荐。
2针灸治疗荷Lewis肺癌小鼠的实验研究
[目的]通过动物实验,建立荷Lewis肺癌小鼠模型,观察针灸对荷Lewis肺癌小鼠的治疗作用及其部分作用机制。
[方法]60只小鼠随机分为4组,每组15只,分别为荷瘤空白组,荷瘤针灸组,荷瘤化疗组,荷瘤化疗针灸组。首先建立Lewis肺癌动物模型。先将液氮冻存的小鼠Lewis肺癌小鼠细胞复苏后,先接种于4只C57BL/6小鼠右腋窝皮下,制备传代荷瘤鼠。传3代后处死小鼠,在无菌条件下剥取荷瘤小鼠瘤块,制备成5×106/ml肿瘤细胞悬液。每只小鼠右侧腋窝皮下接种0.2ml肿瘤细胞悬液。接种后第二天开始治疗,荷瘤化疗组参照张素胤用量(1mg/kg),以DDP溶液0.1ml/20g每日腹腔注射1次,连续10天；荷瘤针灸组取肺俞(双侧交替)、足三里(双侧交替),用30号毫针(0.5寸),常规消毒后直刺0.2-0.3寸,留针5分钟,每日一次,早上10时执行,连续10天；荷瘤化疗针灸组采用荷瘤化疗组及荷瘤针灸组的治疗。
[结果]连续治疗10天后存活小鼠空白组15只,针灸组14只,化疗组12只,针灸化疗组12只。治疗期间死亡率化疗组、针灸化疗组较空白组、针灸组更高,有统计学意义；化疗组较针灸化疗组更高,有统计学意义。
瘤体重量比较：空白组为3.25±0.26g,针灸组为2.84±0.41g,化疗组为2.37±0.47g,针灸化疗组为2.03±0.27g；针灸组、化疗组、针灸化疗组抑瘤率分别为12.58%、27.07%、37.41%；针灸组瘤重与化疗组、针灸化疗组比较,差异均有统计学意义；化疗组与针灸化疗组比较,差异有统计学意义。各组去瘤体重比较：以针灸组最重,其次为空白组、针灸化疗组,化疗组最轻,但四组间差异无统计学意义。
免疫器官重量比较：脾重分别为空白组0.20±0.03g,针灸组0.27±0.06g,化疗组0.18±0.03g,针灸化疗组0.26±0.05g；针灸组与空白组比较,有统计学意义；针灸化疗组与空白组、化疗组比较,有统计学意义。胸腺重量针灸组最重,但四组间无显著性差异。
细胞因子水平比较：血清TNF-α,分别是空白组2.00±0.24ng/m1,针灸组1.96±0.45ng/ml,化疗组2.38±0.28ng/ml,针灸化疗组2.31±0.30ng/ml；TNF-α水平以化疗组最高,其次为针灸化疗组；化疗组、针灸化疗组分别与空白组、针灸组比较均有显著性差异；化疗组和针灸化疗组之间,空白组和中药针灸组之间,均无显著性差异。血清IL-6,分别为126.13±22.85pg/ml,针灸组84.48±15.03pg/ml,化疗组110.78±15.25pg/ml,针灸化疗组90.95±14.72pg/ml；空白组最高,较其他三组有显著性差异；针灸组最低,其次为针灸化疗组,针灸组与化疗组之间有显著性差异,针灸组和针灸化疗组之间无显著性差异。
[结论]针灸治疗对荷瘤小鼠具有一定的抑瘤作用,其作用虽不及化疗明显,但如针灸能联合化疗则较单纯针灸或化疗更能抑制肿瘤进展。该结果与本研究的临床研究结果基本相符,进一步体现中西医综合治疗肿瘤的优势。
针灸可增加免疫器官(脾)的重量,减轻肿瘤及化疗对免疫功能的损害,具有一定的免疫保护作用,可能是针灸抗肿瘤的机制之一。
TNF-α与IL-6水平均可作为监测肺癌病程进展、治疗效果以及疾病预后的辅助指标,同时也与肿瘤导致的虚证密切相关。中医认为,肿瘤产生的基础是正虚,正虚与肿瘤形成及其病机演变、预后等皆有密切关系,而中晚期肺癌多因虚致病,因病致虚,辨证多为虚中夹实或虚实夹杂,肺癌化疗后尤多见脾肾亏虚。因此,扶正补虚是中晚期肺癌的重要治疗原则。针灸具有扶正培本的作用,能明显改善虚证。本研究表明,针灸治疗具有显著降低血清TNF-α和IL-6浓度的作用,提示针灸可能是通过改善肺癌的虚证而达到治疗目的,该作用可能是针灸治疗肺癌产生疗效的重要因素之一。
此外,针灸安全性较好,未见明显副作用。
The incidence rate and the death rate of the lung cancer is very high, most of the patients are on the advanced stage when they are diagnosed. The conventional therapy of lung cancer including the operations、radiotherapy and the chemotherapy has its limit, the effect of the targeted drugs is not certain. The mode of combined therapy is the trend of the treatment of lung cancer. TCM has showed up the superiority of "living with the tumor", but the curative effect are similar in recent years. The acupuncture and moxibustion has the characteristic of innocuousness、ambidirectional dominance and entirety, so it works in the treatment of lung cancer, especially improving symptoms、easing the side effects and raising the curative effect of the radiotherapy and the chemotherapy, and it has little side effect and it charges little. There are many problem in the study and research of the acupuncture and moxibustion, as some of them have no control groups, some have no standard diagnostic criteria、treatment perscription and the evaluation criterion, some have small sample size, and it made the result not confident.This article is about the analysis of curative effect of acupuncture and moxibustion including quality of life、symtoms、side effects of chemotherapy etc in nonsmall-cell lung cance (NSCLC) based on the perspective and control study;and trys to analyse the impact on the of mouse with lung cancer of acupuncture and moxibustion.
1 The analysis of curative effect of acupuncture and moxibustion in NSCLC based on the clinical research.
OBJECTIVE:Observe the curative effect of acupuncture and moxibustion including quality of life、symtoms、side effects of chemotherapy etc in nonsmall-cell lung cance (NSCLC) based on the perspective and control study.
METHODS:From Sep,2008 to Mar,2011,205 patients, with NSCLC in stageⅢ-Ⅳ, were recruited in four hospitals including The 1st affiliated hospital of Guangzhou University of TCM, The 2nd affiliated hospital of Guangzhou University of TCM, Guangzhou Hospital of TCM and Foshan Hospital of TCM.48 cases in group TCM(group T),61 cases in group integrated acupunture with TCM (group A+T),45 cases in group integrated chemotherapy with TCM (group C+T), and 51 cases in group integrated acupunture, chemotherapy with TCM(group A+C+T).
Project for group TCM:with combination of syndrome differen-tiation and disease differentiation, Qingjingdesheng tablets and Shenyi capsules were used according to disease differentiation, and different decoctions were determined from four patterns:phlegmatic stagnation due to passive congestion of lungs (FYTY), phlegmatic hygrosis due to spleen asthenia(PXTS), yin-deficiency and phlegmopyrexia(YXTR) and deficiency ofboth qi and yin(QYLX) according to syndrome diffentiation, and the period of treatment was two courses,21days per course. Project for group integrated acupunture with TCM:the treatment of TCM is the same as group TCM. both Lung Shu, Vital Organs, Diaphragm Shu, Gallbladder Shu and Foot Three Li were chosen in the acupunture therapy, the period of treatment was two courses,21days per course. The first 5 days needling and the last 16 days point application. Project for group integrated chemotherapy with TCM:Platinum-based chemotherapy were used besides the treatment of TCM, either NP/GP/DP regimen or Docetaxel/pemetrexed was adopted, and were repeated every 21days, two times. Project for group integrated acupunture, chemotherapy with TCM:the treatment is the same as the last three groups. The primary points was symptoms improvement, survival, quality of life, side effect of chemotherapy improvement, tumor response rate, ECOG.
RESULTS:Tumor response rate(CR+PR) were 4.17% of group TCM,4.92% of group A+T,24.44% of group C+T,27.45% of group A+C+T;The disease control rate were 56.25%of group TCM,59.02% of group group A+T,75.56% of group of group C+T,86.27% of group A+C+T. There were statistical significance between group T/ A+T with group C+T/ A+C+T; there were statistical significance between group A+C+T and the other groups in the disease control rate.
Symptoms scales changes after treatment of four groups compared:there were statistical significance between group A+C+T and the other groups, there were statistical significance between group C+T and the group T/ A+T.
PS scales decrease after treatment of four groups compared:there were statistical significance between group A+C+T and the other groups, there were statistical significance between group C+T and the group T/ A+T.
The quality of life changes after treatment of four groups compared: group A+T and group T inproved after the treatment, but group C+T and group A+C+T decreased after the treatment. There were statistical significance between the group A+T and the group T in the emotional condition funtional condition and lung cancer information. And acupunture works for all types of syndrome, especially for the patients who have got phlegmatic hygrosis dueto spleen asthenia(PXTS).
Most of the side effect scales worsened after the treatment of group C+T and group A+C+T. Refers to the symtoms like nausea and vomitting、diarrhoea constipation and pruritus, there were statistical significance between group C+T and group A+C+T.
WBC and PLT scales changed after treatment of four groups compared: there were statistical significance between group T/ A+T and other two groups, there were statistical significance between group A+C+T and group C+T, there were statistical significance between group A+T and the group T.
CEA、CA125、CA199 decreased after the treatment of four groups;CEA、CA199 in group C+T、group A+C+T decreased more than group A+T and group T. Group A+C+T was the lowest, and there were statistical significance between group A+C+T and the other three groups.
The heart function、Hepatic function and renal function of the patients has not getten worse after the acupumture therapy. Some patients got subcutaneous hemorrhage、pain after the treatment. The common side effects were erubescence and pruritus. The side effects could be cured, and so the acupumture therapy is safe.
CONCLUSI ONS:The treatment integrated acupumture with TCM is better at stabilizing hemogram、improving the quality of life such as emotional condition functional condition and lung cancer imformation than TCM. The treatment integrated chemotherapy、acupumture and TCM is better at improving the sympton、decreasing PS、stabilizing hemogram、increasing the disease control rate、decreasing the side effect of chemotherapy and decreasing CA125 than the treatment integrated chemotherapy and TCM. According to the disease control rate、symptoms improvement tumor markers, acupumture can elevate the effect of chemotherapy. According to the symptoms improvement PS decrease、hemogram、side effect of chemotherapy, acupumture can degrade the toxicity of chemotherapy. And acupunture works for all types of syndrome, especially for the patients who have got phlegmatic hygrosis dueto spleen asthenia(PXTS).
According to the disease control rate、symptoms improvement、PS decrease and tumor markers, the treatment integrated chemotherapy、acupumture with TCM is the best way to cure NSCLC. And acupumture is very safe.
2 The Experimental Research of acupumture in Treatment of Lewis Lung Cancer(LLC) Mice
OBJECTIVE:To analyse the effect of acupuncture and moxibustion on the mice with lung cancer.
METHODS:60 C57BL/6 mice were randomly divided into four groups, there were15 mice each group, and four groups as follows:LLC blank (group A), LLC acupumture (group B), LLC chemotherapy(group C) and LLC acupumture and chemotherapy(group D).Step 1:After awaking LLC cells to be frozen by liguid nitrogen, four C57BL/6 mice'right axilla subcutaneous part were inoculated by LLC cells 2.5×105, for establishing transfer of culture LLC mice. The mice were killed after transfer to three generation, and tumor was taken in sterile to make tumor cell suspension which concentration was 5×106/ml. Every mouse'right axilla subcutaneous part was inoculated by 0.2ml tumor cell suspension. On the second day Post inoculation, treatment began. In group B, Both Lung Shu, Foot Three Li were chosen in the acupunture therapy, and every day for 10 days.Group C were administrated intraperitoneal cisplatin by 0. lml/20g every day for 10 days. Group D took the same treatment with group B and group C.
RESULTS:After continues treatment for ten days, survival mice number of group A, B, C and D were 15,14,12 and 12 respectively。The death rate of group C and D is higher than group A and B, and group C is higher than group D. Weight of tumor of group A, B, C and D were 3.25±0.26g,2.84±0.41g,2.37±0.47g and 2.03±0.27g respectively;There were statistical significance between group B and group C or D; there were statistical significance between group C and D. Suppress tumor rate of group B、C and D were 12.58%、27.07%、37.41% respectively. Body weight except tumor of group compared:group B is the heavest, but there was no statistical significance between groups.
Weight of spleen of group A, B, C and D were 0.20±0.03g,0.27±0.06g, 0.18±0.03g and 0.26±0.05g respectively;Weight of thymus gland of group A, B, C and D were 0.055±0.016g,0.036±0.015g,0.031±0.008g and 0.045±0.012g respectively;there were statistical significance between group A and group B; there were statistical significance between group D and group A or C. Weight of thymus gland compared:group B is the heavies, but there was no statistical significance between groups.
Serum TNF-αlevel of group A, B, C and D were 2.00±0.24ng/ml,1.96±0.45ng/ml,2.38±0.28ng/ml,2.31±0.30ng/ml respectively;there were statistical significance between group C/D and group A/B, but there was no statistical significance between group A and B or C and D. Serum IL-6 levels of group A, B, C and D were 126.13±22.85pg/ml,84.48±15.03pg/ml, 110.78±15.25pg/ml,90.95±14.72pg/ml respectively;there were statistical significance between group A and the other groups;there were statistical significance between group B and C.
CONCLUSIONS:The treatment of acupumture could suppress tumor growth of LLC mice, which was weaker than chemotherapy, but acupumture integrated with chemotherapy would be better than acupumture only or chemotherapy only.
The treatment of acupumture could increase the weight of LLC mice spleen to some extent, and enhance immune function of animal body to some extent.
TNF-αand IL-6 is the index that could reflect the lung cancer aggravation therapeutic efficacy and the prognosis, and correlates to the deficient syndrome. Acupumture could decrease serum TNF-αand IL-6 levels significantly, which may be one of important reasons for treating the lung cancer.
引文
[1]Gridelli C, Rossi A, Maione P:Treatment of non-small-cell lung cancer:state of the art and development of new biologic agents. Oncogene 2003,22:6629-6638
[2]David G. Pfister, David H. et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline:Update 2003.J Clin Oncol2003,22:330-353
[3]Cesare Gridelli. Targeted therapies in the treatment of non small cell lung cancer:reality and hopes. Current Opinion in Oncology 2004,16:126-129
[4]王树堂,“带瘤生存”为癌症治疗带来新观念——周岱翰教授诠释中医肿瘤学,新中医,2009年7月,41(7)：107-108
[5]孙钢,刘嘉湘.肺癌的中医药治疗进展与思考.江苏中医,2000,21(1)：44
[6]刘嘉湘, 潘敏求, 黎月恒,叶大茜,郭映华,李涌健.金复康口服液治疗原发性非小细胞肺癌临床研究.肿瘤,2001,21(6)：463-465
[7]刘嘉湘,施志明等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察.上海中医药杂志,2001,(2)：4-6
[8]孙大兴,裘维焰,赵树珍.肺康方治疗中晚期非小细胞肺癌疗效分析,中医药学报,2002,30(2)：49-50
[9]陈志峰,李成柱,刘少翔.中医药治疗原发性非小细胞肺癌疗效的Meta分析.中医杂志1999；40(5)：287-288.
[10]刘立公顾杰,肿瘤相关病症的古代针灸治疗特点,上海中医药大学学报,第17卷第1期,2003年3月：33-35
[11]夏玉卿.电热针治疗皮肤癌疗效及机理研究.中国针灸,1994,14(2)：5
[12]赵文生,针刺治疗食道癌306例临床报道[J].中国针灸,1988,8(1)：23
[13]吴耀持,毫米波循经传导穴位辐照治疗肿瘤的作用,上海针灸杂志,1998,17(2)： 15
[14]田菲贾英杰陈军等,温针灸对于恶性肿瘤患者的免疫微生物调控[J],针灸临床杂志,1999,15(5)：48
[15]卞镝,张宁苏,成泽东,等.穴位注射加灸对癌痛患者外周血中β-内啡肽的影响[J].辽宁中医杂志,2004,31(3)：246-247
[16]黄喜梅.针刺配合艾炷灸治疗化疗引起的泄泻70例.河南中医,1996,16 (3)：174
[17]王守章,杨学峰1针刺控制化疗所致胃肠反应的临床研究[J]中国针灸,1997,17(1)：17
[18]周俊青、徐天舒、钱雷,针灸对肿瘤患者化疗后血细胞和消化道反应的影响,中国针灸2004年11月第24卷第11期：741-743
[19]Shen J, WengerN, Glaspy J, et a.1 Electroacupuncture for control of myeloablative chemotherapy-induced emesis:A randomized controlled trial[J]. JAMA,2000,284(21):275517-61
[20]马婷婷,陈勤,梁繁荣,针灸治疗化疗所致恶心呕吐的国内外临床研究对比,辽宁中医杂志2009年第36卷第4期,612-614
[21]Gardani G, Cerrone R, Biella C, etal.A progreas study of 100 cancer patients treated by acupressure for chemotherapy-induced vomiting after failure with the pharmacological approach. Minerva Med.2007,98(6):665-668
[22]Shen J, Wenger N, Glaspy J, etal. Electroacupuncture for control fo myeloablative chemotherapy-induced emesia:a randomized controlled trial. JAMA.2000,284(21):2755-2761
[23]黄喜梅.电针足三里穴对癌症化疗中胃肠功能影响的临床及实验研究[J].上海针灸杂志.1996,15(3)：11-13
[24]李英 冯秀明,黄喜梅1电针对放化疗大鼠胃肠功能影响的实验研究[J],中国针灸,1996,16(3)：146
[25]李晔.针刺治疗恶性肿瘤放化疗副反应的临床研究.中国针灸,1997,17(6)：327
[26]路玫.针灸治疗肿瘤患者化疗致白细胞减少症疗效及机制研究[J].中国针灸,1997,17(10)：583
[27]徐淑英 徐瞒英,癌性腹痛应用针刺足三里穴镇痛临床观察[J],实用中西医结合杂志,1994,7(1)：22
[28]孙亚林 于连荣.齐刺留针法治疗肝癌疼痛80例疗效观察.中国针灸.2000;20(4)：211-212
[29]李艳春 姜赛林 李飞跃等,针刺对晚期肿瘤患者的止痛研究,长春中医学院学报,1998,14(3)：29
[30]章梅 夏天 吴少华等,针刺和中药对癌症疼痛镇痛作用的临床研究, 针刺研究,2000,25(1)：64-66
[31]卞镝 成泽东 张宁苏,穴位注射加灸对癌痛患者外周血中IL-2/IL-2R表达的影响,中国针灸,2004,24(9)：641-644
[32]赵喜新,针灸对环磷酰胺小鼠血清集落刺激因子的影响,中医研究,1996,9 (4)：33
[33]赵喜新,针灸对化疗小鼠白细胞动态变化的影响,河南中医,1996,16(4)：216
[34]路玫 曹大明 赵喜新,针灸对CTX荷瘤小鼠骨髓细胞DNA修复基因MGMTmRNA POLβ mRNA表达的调控研究,辽宁中医杂志,2010年第37卷第10期：1901-1904
[35]刘宏伟 庞波 冯晓东等,针灸对荷瘤动物若干免疫学指标的影响[J],中医研究,1995,(4)：50
[36]刘志丹 裴建 傅勤慧,针灸及其血清对荷瘤小鼠CD4+、CD25+Treg细胞体外增殖的影响,针刺研究,2009年8月,第34卷第4期：219-224
[37]杨志新,艾灸增强小鼠巨噬细胞抗肿瘤作用的研究,针灸临床杂志,2001年,第17卷第8期：54-55
[38]李海燕 裴建 刘志丹,针灸对荷瘤小鼠脾淋巴细胞增殖及Stat5-Foxp3通路影响,上海针灸杂志,2010年3月,第29卷第3期：190-194
[39]唐照亮 陈森和 宋小鸽等,艾灸抗小鼠S180实体瘤的实验研究,针刺研究,1999,24(1)：6]
[40]叶向荣 张素芬 张丹等,艾灸神阙穴抗癌的实验研究,山东中医药大学学报,2000,24(3)：229
[41]陈云飞 赵粹英 陈汉平等,小鼠艾灸血清诱导肿瘤细胞凋亡的实验研究,针刺研究,2000,25(1)：38
[42]Lee HJ Lee EO etal, Substance P and beta endorphinmediate electro acupuncture induced analgesic activity in mouse cancer pain model [J], Acupuncture ElectrotherRes,2009,34(1-2):27-40
[43]Zhang RX, Li A, Liu B, etal.Electroacupuncture attenuates bone-cancer-induced hyperalgesia and inhibits spinal preprodynorphin expression in a rat model. Eur J Pain,2008,12(7):870-878
[44]陈新 史静,鸡血藤与针灸联合治疗化疗后白细胞减少症185例,河北中西医结合杂志,1998年,7(11)：1782
[45]梁雅珍 王丽坤 张钧等,针灸治疗放化疗患者白细胞低下的临床观察,上海针灸杂志,1996年,15(6)：11
[46]李学武 李南玲 赵立岩等,斑蝥灸对肺癌小鼠nm23-1基因表达的实验,中国临床康复,2006年,第9卷第47期：96-98
[47]李磊 陈汉平,不同时辰针灸不同穴位对Lewis肺癌小鼠免疫和生化指标的影响,天津中医学院学报,1994年第4期：24-25
[48]王颖 李学武 赵立岩,天灸对肺癌小鼠骨髓有核细胞和外周白细胞的影响及其抗肿瘤作用,中国临床康复,2006年,第10卷第11期：132-134
[49]李岩郭刚王玫,针灸大鼠血清诱导人肺癌A549细胞凋亡的研究,山东中医药大学学报,2005年9月,第29卷第5期：400-401
[50]孙国杰等,针灸学上海科学技术出版社1997年：23-25
[51]张凤娥罗玉清苏筱玲,针灸的双向调节作用与免疫机制探讨,中国科技信息,2005年第16期：271
[52]陈少宗,针刺效应与机体机能状态数量关系的初步观察,中国针灸,1993,5： 41
[53]骆永珍张燕华周荣光,针灸与免疫[M],北京,人民卫生出版社,2002,13
[54]于颖梅裴建吴焕淦等,针灸调节免疫抑制的研究进展[J],江西中医学院学报,2003,15(3)：372
[55]戴颖刘运泉宿宝贵等,针灸治疗脑梗塞的免疫调控机制[J],中华实用中西医杂志,2003,3(16)：10472-10481
[56]汪军姜建伟蔡三军等,电针对消化道肿瘤患者围手术及围化疗期T淋巴细胞亚群和淋巴细胞转化功能的影响,上海针灸杂志,2004,23(11)：5
[57]朱梅,针刺“足三里”、“关元”穴区对老年大鼠肝脏内巨噬细胞功能影响的实验研究[J],针灸临床杂志,2003,19(6)：52-53
[58]贾振和 薛芙蕖 吕晔等,脐血足三里穴位注射治疗化疗所致白细胞减少46例疗效观察[J],中国针灸,2000,(10)：585
[59]Fang Y, Deshan L, ShuliW, et al. Effects of Electro-acupuncture on Tcell Subpopulations, NK Activity, Humoral Immunity and Leukocyte Count in PatientsUndergoing Chemotherapy[J]. Journal of Traditional Chinese Medicine.2007,27 (1):19
[60]魏赞美庄启岚,针刺足三里治疗白细胞减少症及对免疫功能的观察[J],上海针灸杂志,1996,15(6)：12
[61]陈德成吴旭吴文忠等,穴位注射对慢性萎缩胃炎患者免疫调节作用机理研究[J],中国针灸,1998,18(2)：692
[62]郑真,针灸在肿瘤综合治疗中的作用[J],南京中医学院学报,1994,(3)：47
[63]吴滨周荣兴何况,针灸对免疫功能调节的研究现状与展望[J],上海针灸杂志,1999,18(1)：46
[64]陈雄华,针灸抗肿瘤免疫效应的临床与实验研究概况[J],湖北中医杂志,1998,(5)：59
[65]杨晋塑译,针灸治疗癌症病人的经验[J],国外医学·中医中药分册,1991,(3)：25
[66]邓德厚,癌性疼痛的针灸治疗研究进展,中医药学报,2010年第38卷第5 期：141-44
[67]耿志国,针灸治疗癌性疼痛和放、化疗反应的临床疗效观察[J],中国冶金工业医学杂志,2005,22(3)：362
[68]钭志萍 雷永海 郑桂爱等,足三里穴穴位注射对胃癌终末期镇痛作用观察[J],浙江中西医结合杂志,2004,14(9)：538-539
[69]傅强熊拥军李若兰,恩丹西酮联合针刺对化疗所致恶心与呕吐的疗效分析[J],中国综合临床,2003,19(3)：245-246.
[70]周丽胡慧李泉旺,公孙、内关为主针刺防治化疗性呕吐疗效观察[J],山东中医杂志,2006,25(6)：392-393
[71]曹海青 李艳红,针刺在NP方案治疗非小细胞肺癌患者中对延迟性恶心呕吐的控制[J],中国癌症杂志,2006,16(9)：751-752
[72]施琴,针刺足三里、内关穴预防化疗胃肠道反应疗效观察[J],中医药临床杂志,2004,16(5)：481
[73]阙铁生 吕军影 黄耀全,针刺防治顺铂化疗所致呕吐的临床观察[J],上海针灸杂志,2003,22(4)：8-9
[74]StreitbergerK, Friedrich-RustM, BardenheuerH, etal. Effectofacupun-cture compared with placeboacupuncture at P6 as additional antiemetic pro-phylaxis in high-dose chemotherapy and autologous peripheralblood stem cell transplantation:a randomized controlled single-blind trial[J].Clin CancerRes,2003,9(7):2538-2544
[75]TobiasK Reind, Wilhelm Geilen, Reinhard Hartmann, etal, Acupuncture against chemotherapy-induced nausea and vomiting in pediatric oncology Interim results of a multicenter crossover study [J]. SupportCare Cancer,2006, 14:172-176
[76]史晓岚,针灸防治肿瘤化疗毒副反应[J], Chinese Jounal of Celiopathy April,2006, Vol6,No4
[77]赵小青 郭晓园,针灸治疗肿瘤化疗后所致骨髓抑制38例[J],山东中医杂志,2001,20(5)：349
[78]何巍 赵英凯 李凤玲等,基于PUBMED文献的国外针灸治疗癌症的现状分析,国际中医中药杂志,2010年1月,32(1)：70-71
[79]中华医学会编著,临床诊疗指南·肿瘤分册,北京：人民卫生出版社,2005：99-107
[80]周岱翰,肿瘤经验集要,广东高等教育出版社,1997：139
[81]郑筱萸主编,《中药新药临床研究指导原则》,中国医药科技出版社,2002年5月第一版：
[82]周岱翰主编,临床中医肿瘤学,人民卫生出版社,2003年4月第一版
[83]李忠仁主编,实验针灸学,中国中医药出版社,2003年1月第一版：125-126
[84]吕琳,针灸调节肿瘤免疫的临床及实验研究进展,辽宁中医杂志,第28卷,第10期,2001年10月：638-640
[85]黄喜梅.艾炷灸治疗化疗引起白细胞降低114例报告.中医杂志,1990,31(2)： 48
[86]杨甲三主编,腧穴学,上海科学技术出版社,1984： 179
[87]Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med.1981 Jun;51(3):191-204
[88]Rice GE, Gimbrone MA Jr, Bevilacqua MP. Tumor cell-endothelial interactions. Increased adhesion of human melanoma cells to activated vascular endothelium. Am JPathol.1988 Nov;133(2):204-210
[89]Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-alpha:effects on pro-liferation of normal and transformed cells in vitro. Science.1985 Nov 22; 230(4728):943-945
[90]Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metallop-roteinases (TIMP) production by human fibroblasts. FEBS Lett.1990 Aug 20; 269(1):93-95
[91]马路 周厚清 李成继,肺癌患者血清中炎症因子的水平研究,中国卫生检验杂志,2008年8月,第18卷第8期：1575-1576
[92]蔡娟 殷少军 许福亮等,肿瘤坏死因子α在非小细胞肺癌患者中的临床价值探讨,中国肿瘤临床与康复,2002,9(4)：34-35.
[93]孙玉萍 陈秀杉 窦岩等,血清IL-6和TNF-α监测老年肺癌病情进展及预后的临床研究,山东医科大学学报,1999,37(2)：144-147
[94]李宏云 郑红 姚反修等,化疗药物对肺癌患者血清肿瘤坏死因子的影响,河南医科大学学报,2001,36(3)：337-338
[95]梁翠微 杨兵 杜均祥,晚期肺癌恶病质中医辨证分型及细胞因子变化,安徽中医学院学报,2010年12月,第29卷第6期：33-35
[96]Esper DH, Harb WA. The cancer cachexia syndrome:areview of metabolic and clinical manifestations[J]. NutrClin Pract,2005,20(4):369-376
[97]The role of cytokines in cancer cachexia[J]. Med ResRev,1999,19 (3):223-248
[98]Hirano T. Interleukin 6. In:Thomson A, editor. The cytokine hand- book, London:Academic Press;1994.145-168
[99]Kitaoka T, Fukada T, Hibi M, Hirano T. A central role for tat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996,15:3651-3658
[100]Miki S, Iwano M, Miki Y, etal, Interleukin-6 (IL-6) functionsas an invitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250:607-610
[101]Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57:141-146
[102]余寿益 田华琴 黄志庆等,肺癌患者血清sIL-R2、IL-6和TNF-α水平的测定及其临床意义,癌症,2002,19(10)：945
[103]匡弢 王秀美 曹志红,肺癌患者血清sIL-2R、sIL-6R和TNF-α水平变化及意义,山东医药,2004年,第44卷第7期：50
[104]李国玲 邓星奇 王喜英,肺癌患者血清白细胞介素6、可溶性白细胞介素6受体的测定及其临床意义,实用医学杂志,2009年,第25卷第8期：1246-1247
[105]Yanagawa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer.1995 May;71 (5):1095-1098
[106]Burger RA, Grosen EA, Ioli GR, etal. Spontaneous release of inter-leukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovrian carcinoma. Interferon Cytokine Research,1995;15 (3):255-260
[107]周欢琴 翁秀妹 叶雄伟,肺癌患者血清VEGF-C、IL-6和TNF-α水平变化的临床观察,全科医学临床与教育,2010年11月,第八卷第6期：665-666
[108]刘铁梅 赵凤芹 朱光泽,肺癌患者血清sIL-2R、IL-6和TNF-α水平的测定及临床意义,吉林大学学报 (医学版),2002年,第28卷第1期：55-56
[109]郑亚兵 马胜林 周卫民等,参附注射液抗Lewis肺癌小鼠癌性恶液质的肺癌小鼠癌性恶液质的实验研究[J],中华中医药杂志,2009,24(3)：380-382.
[110]De Vita F, Orditura M, Auriemma A, et al. Serum levels of interleukin-6 as aprognostic factor in advanced non-small cell lung cancer. Oncol Rep.1998 May-Jun;5(3):649-52
[111]Scott HR, McMillan DC, Crilly A, et al. The relationship between weight loss andinterleukin 6 in non-small-cell lung cancer. Br J Cancer.1996 Jun; 73(12):1560-2
[112]Ohira T, Nishio K, Ohe Y et al. Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. J. Cancer Res. Clin. Oncol,1996, 122,711-715
[113]Ohe Y, Podack E R, Olsen K J, et al. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shorten survival in syngeneic mice. Br. J. Cancer,67,939-944
[2]David G. Pfister, David H. et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline:Update 2003.J Clin Oncol2003,22:330-353
[3]Cesare Gridelli. Targeted therapies in the treatment of non small cell lung cancer:reality and hopes. Current Opinion in Oncology 2004,16:126-129
[4]王树堂,“带瘤生存”为癌症治疗带来新观念——周岱翰教授诠释中医肿瘤学,新中医,2009年7月,41(7)：107-108
[5]孙钢,刘嘉湘.肺癌的中医药治疗进展与思考.江苏中医,2000,21(1)：44
[6]刘嘉湘, 潘敏求, 黎月恒,叶大茜,郭映华,李涌健.金复康口服液治疗原发性非小细胞肺癌临床研究.肿瘤,2001,21(6)：463-465
[7]刘嘉湘,施志明等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察.上海中医药杂志,2001,(2)：4-6
[8]孙大兴,裘维焰,赵树珍.肺康方治疗中晚期非小细胞肺癌疗效分析,中医药学报,2002,30(2)：49-50
[9]陈志峰,李成柱,刘少翔.中医药治疗原发性非小细胞肺癌疗效的Meta分析.中医杂志1999；40(5)：287-288.
[10]刘立公顾杰,肿瘤相关病症的古代针灸治疗特点,上海中医药大学学报,第17卷第1期,2003年3月：33-35
[11]夏玉卿.电热针治疗皮肤癌疗效及机理研究.中国针灸,1994,14(2)：5
[12]赵文生,针刺治疗食道癌306例临床报道[J].中国针灸,1988,8(1)：23
[13]吴耀持,毫米波循经传导穴位辐照治疗肿瘤的作用,上海针灸杂志,1998,17(2)： 15
[14]田菲贾英杰陈军等,温针灸对于恶性肿瘤患者的免疫微生物调控[J],针灸临床杂志,1999,15(5)：48
[15]卞镝,张宁苏,成泽东,等.穴位注射加灸对癌痛患者外周血中β-内啡肽的影响[J].辽宁中医杂志,2004,31(3)：246-247
[16]黄喜梅.针刺配合艾炷灸治疗化疗引起的泄泻70例.河南中医,1996,16 (3)：174
[17]王守章,杨学峰1针刺控制化疗所致胃肠反应的临床研究[J]中国针灸,1997,17(1)：17
[18]周俊青、徐天舒、钱雷,针灸对肿瘤患者化疗后血细胞和消化道反应的影响,中国针灸2004年11月第24卷第11期：741-743
[19]Shen J, WengerN, Glaspy J, et a.1 Electroacupuncture for control of myeloablative chemotherapy-induced emesis:A randomized controlled trial[J]. JAMA,2000,284(21):275517-61
[20]马婷婷,陈勤,梁繁荣,针灸治疗化疗所致恶心呕吐的国内外临床研究对比,辽宁中医杂志2009年第36卷第4期,612-614
[21]Gardani G, Cerrone R, Biella C, etal.A progreas study of 100 cancer patients treated by acupressure for chemotherapy-induced vomiting after failure with the pharmacological approach. Minerva Med.2007,98(6):665-668
[22]Shen J, Wenger N, Glaspy J, etal. Electroacupuncture for control fo myeloablative chemotherapy-induced emesia:a randomized controlled trial. JAMA.2000,284(21):2755-2761
[23]黄喜梅.电针足三里穴对癌症化疗中胃肠功能影响的临床及实验研究[J].上海针灸杂志.1996,15(3)：11-13
[24]李英 冯秀明,黄喜梅1电针对放化疗大鼠胃肠功能影响的实验研究[J],中国针灸,1996,16(3)：146
[25]李晔.针刺治疗恶性肿瘤放化疗副反应的临床研究.中国针灸,1997,17(6)：327
[26]路玫.针灸治疗肿瘤患者化疗致白细胞减少症疗效及机制研究[J].中国针灸,1997,17(10)：583
[27]徐淑英 徐瞒英,癌性腹痛应用针刺足三里穴镇痛临床观察[J],实用中西医结合杂志,1994,7(1)：22
[28]孙亚林 于连荣.齐刺留针法治疗肝癌疼痛80例疗效观察.中国针灸.2000;20(4)：211-212
[29]李艳春 姜赛林 李飞跃等,针刺对晚期肿瘤患者的止痛研究,长春中医学院学报,1998,14(3)：29
[30]章梅 夏天 吴少华等,针刺和中药对癌症疼痛镇痛作用的临床研究, 针刺研究,2000,25(1)：64-66
[31]卞镝 成泽东 张宁苏,穴位注射加灸对癌痛患者外周血中IL-2/IL-2R表达的影响,中国针灸,2004,24(9)：641-644
[32]赵喜新,针灸对环磷酰胺小鼠血清集落刺激因子的影响,中医研究,1996,9 (4)：33
[33]赵喜新,针灸对化疗小鼠白细胞动态变化的影响,河南中医,1996,16(4)：216
[34]路玫 曹大明 赵喜新,针灸对CTX荷瘤小鼠骨髓细胞DNA修复基因MGMTmRNA POLβ mRNA表达的调控研究,辽宁中医杂志,2010年第37卷第10期：1901-1904
[35]刘宏伟 庞波 冯晓东等,针灸对荷瘤动物若干免疫学指标的影响[J],中医研究,1995,(4)：50
[36]刘志丹 裴建 傅勤慧,针灸及其血清对荷瘤小鼠CD4+、CD25+Treg细胞体外增殖的影响,针刺研究,2009年8月,第34卷第4期：219-224
[37]杨志新,艾灸增强小鼠巨噬细胞抗肿瘤作用的研究,针灸临床杂志,2001年,第17卷第8期：54-55
[38]李海燕 裴建 刘志丹,针灸对荷瘤小鼠脾淋巴细胞增殖及Stat5-Foxp3通路影响,上海针灸杂志,2010年3月,第29卷第3期：190-194
[39]唐照亮 陈森和 宋小鸽等,艾灸抗小鼠S180实体瘤的实验研究,针刺研究,1999,24(1)：6]
[40]叶向荣 张素芬 张丹等,艾灸神阙穴抗癌的实验研究,山东中医药大学学报,2000,24(3)：229
[41]陈云飞 赵粹英 陈汉平等,小鼠艾灸血清诱导肿瘤细胞凋亡的实验研究,针刺研究,2000,25(1)：38
[42]Lee HJ Lee EO etal, Substance P and beta endorphinmediate electro acupuncture induced analgesic activity in mouse cancer pain model [J], Acupuncture ElectrotherRes,2009,34(1-2):27-40
[43]Zhang RX, Li A, Liu B, etal.Electroacupuncture attenuates bone-cancer-induced hyperalgesia and inhibits spinal preprodynorphin expression in a rat model. Eur J Pain,2008,12(7):870-878
[44]陈新 史静,鸡血藤与针灸联合治疗化疗后白细胞减少症185例,河北中西医结合杂志,1998年,7(11)：1782
[45]梁雅珍 王丽坤 张钧等,针灸治疗放化疗患者白细胞低下的临床观察,上海针灸杂志,1996年,15(6)：11
[46]李学武 李南玲 赵立岩等,斑蝥灸对肺癌小鼠nm23-1基因表达的实验,中国临床康复,2006年,第9卷第47期：96-98
[47]李磊 陈汉平,不同时辰针灸不同穴位对Lewis肺癌小鼠免疫和生化指标的影响,天津中医学院学报,1994年第4期：24-25
[48]王颖 李学武 赵立岩,天灸对肺癌小鼠骨髓有核细胞和外周白细胞的影响及其抗肿瘤作用,中国临床康复,2006年,第10卷第11期：132-134
[49]李岩郭刚王玫,针灸大鼠血清诱导人肺癌A549细胞凋亡的研究,山东中医药大学学报,2005年9月,第29卷第5期：400-401
[50]孙国杰等,针灸学上海科学技术出版社1997年：23-25
[51]张凤娥罗玉清苏筱玲,针灸的双向调节作用与免疫机制探讨,中国科技信息,2005年第16期：271
[52]陈少宗,针刺效应与机体机能状态数量关系的初步观察,中国针灸,1993,5： 41
[53]骆永珍张燕华周荣光,针灸与免疫[M],北京,人民卫生出版社,2002,13
[54]于颖梅裴建吴焕淦等,针灸调节免疫抑制的研究进展[J],江西中医学院学报,2003,15(3)：372
[55]戴颖刘运泉宿宝贵等,针灸治疗脑梗塞的免疫调控机制[J],中华实用中西医杂志,2003,3(16)：10472-10481
[56]汪军姜建伟蔡三军等,电针对消化道肿瘤患者围手术及围化疗期T淋巴细胞亚群和淋巴细胞转化功能的影响,上海针灸杂志,2004,23(11)：5
[57]朱梅,针刺“足三里”、“关元”穴区对老年大鼠肝脏内巨噬细胞功能影响的实验研究[J],针灸临床杂志,2003,19(6)：52-53
[58]贾振和 薛芙蕖 吕晔等,脐血足三里穴位注射治疗化疗所致白细胞减少46例疗效观察[J],中国针灸,2000,(10)：585
[59]Fang Y, Deshan L, ShuliW, et al. Effects of Electro-acupuncture on Tcell Subpopulations, NK Activity, Humoral Immunity and Leukocyte Count in PatientsUndergoing Chemotherapy[J]. Journal of Traditional Chinese Medicine.2007,27 (1):19
[60]魏赞美庄启岚,针刺足三里治疗白细胞减少症及对免疫功能的观察[J],上海针灸杂志,1996,15(6)：12
[61]陈德成吴旭吴文忠等,穴位注射对慢性萎缩胃炎患者免疫调节作用机理研究[J],中国针灸,1998,18(2)：692
[62]郑真,针灸在肿瘤综合治疗中的作用[J],南京中医学院学报,1994,(3)：47
[63]吴滨周荣兴何况,针灸对免疫功能调节的研究现状与展望[J],上海针灸杂志,1999,18(1)：46
[64]陈雄华,针灸抗肿瘤免疫效应的临床与实验研究概况[J],湖北中医杂志,1998,(5)：59
[65]杨晋塑译,针灸治疗癌症病人的经验[J],国外医学·中医中药分册,1991,(3)：25
[66]邓德厚,癌性疼痛的针灸治疗研究进展,中医药学报,2010年第38卷第5 期：141-44
[67]耿志国,针灸治疗癌性疼痛和放、化疗反应的临床疗效观察[J],中国冶金工业医学杂志,2005,22(3)：362
[68]钭志萍 雷永海 郑桂爱等,足三里穴穴位注射对胃癌终末期镇痛作用观察[J],浙江中西医结合杂志,2004,14(9)：538-539
[69]傅强熊拥军李若兰,恩丹西酮联合针刺对化疗所致恶心与呕吐的疗效分析[J],中国综合临床,2003,19(3)：245-246.
[70]周丽胡慧李泉旺,公孙、内关为主针刺防治化疗性呕吐疗效观察[J],山东中医杂志,2006,25(6)：392-393
[71]曹海青 李艳红,针刺在NP方案治疗非小细胞肺癌患者中对延迟性恶心呕吐的控制[J],中国癌症杂志,2006,16(9)：751-752
[72]施琴,针刺足三里、内关穴预防化疗胃肠道反应疗效观察[J],中医药临床杂志,2004,16(5)：481
[73]阙铁生 吕军影 黄耀全,针刺防治顺铂化疗所致呕吐的临床观察[J],上海针灸杂志,2003,22(4)：8-9
[74]StreitbergerK, Friedrich-RustM, BardenheuerH, etal. Effectofacupun-cture compared with placeboacupuncture at P6 as additional antiemetic pro-phylaxis in high-dose chemotherapy and autologous peripheralblood stem cell transplantation:a randomized controlled single-blind trial[J].Clin CancerRes,2003,9(7):2538-2544
[75]TobiasK Reind, Wilhelm Geilen, Reinhard Hartmann, etal, Acupuncture against chemotherapy-induced nausea and vomiting in pediatric oncology Interim results of a multicenter crossover study [J]. SupportCare Cancer,2006, 14:172-176
[76]史晓岚,针灸防治肿瘤化疗毒副反应[J], Chinese Jounal of Celiopathy April,2006, Vol6,No4
[77]赵小青 郭晓园,针灸治疗肿瘤化疗后所致骨髓抑制38例[J],山东中医杂志,2001,20(5)：349
[78]何巍 赵英凯 李凤玲等,基于PUBMED文献的国外针灸治疗癌症的现状分析,国际中医中药杂志,2010年1月,32(1)：70-71
[79]中华医学会编著,临床诊疗指南·肿瘤分册,北京：人民卫生出版社,2005：99-107
[80]周岱翰,肿瘤经验集要,广东高等教育出版社,1997：139
[81]郑筱萸主编,《中药新药临床研究指导原则》,中国医药科技出版社,2002年5月第一版：
[82]周岱翰主编,临床中医肿瘤学,人民卫生出版社,2003年4月第一版
[83]李忠仁主编,实验针灸学,中国中医药出版社,2003年1月第一版：125-126
[84]吕琳,针灸调节肿瘤免疫的临床及实验研究进展,辽宁中医杂志,第28卷,第10期,2001年10月：638-640
[85]黄喜梅.艾炷灸治疗化疗引起白细胞降低114例报告.中医杂志,1990,31(2)： 48
[86]杨甲三主编,腧穴学,上海科学技术出版社,1984： 179
[87]Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med.1981 Jun;51(3):191-204
[88]Rice GE, Gimbrone MA Jr, Bevilacqua MP. Tumor cell-endothelial interactions. Increased adhesion of human melanoma cells to activated vascular endothelium. Am JPathol.1988 Nov;133(2):204-210
[89]Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-alpha:effects on pro-liferation of normal and transformed cells in vitro. Science.1985 Nov 22; 230(4728):943-945
[90]Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metallop-roteinases (TIMP) production by human fibroblasts. FEBS Lett.1990 Aug 20; 269(1):93-95
[91]马路 周厚清 李成继,肺癌患者血清中炎症因子的水平研究,中国卫生检验杂志,2008年8月,第18卷第8期：1575-1576
[92]蔡娟 殷少军 许福亮等,肿瘤坏死因子α在非小细胞肺癌患者中的临床价值探讨,中国肿瘤临床与康复,2002,9(4)：34-35.
[93]孙玉萍 陈秀杉 窦岩等,血清IL-6和TNF-α监测老年肺癌病情进展及预后的临床研究,山东医科大学学报,1999,37(2)：144-147
[94]李宏云 郑红 姚反修等,化疗药物对肺癌患者血清肿瘤坏死因子的影响,河南医科大学学报,2001,36(3)：337-338
[95]梁翠微 杨兵 杜均祥,晚期肺癌恶病质中医辨证分型及细胞因子变化,安徽中医学院学报,2010年12月,第29卷第6期：33-35
[96]Esper DH, Harb WA. The cancer cachexia syndrome:areview of metabolic and clinical manifestations[J]. NutrClin Pract,2005,20(4):369-376
[97]The role of cytokines in cancer cachexia[J]. Med ResRev,1999,19 (3):223-248
[98]Hirano T. Interleukin 6. In:Thomson A, editor. The cytokine hand- book, London:Academic Press;1994.145-168
[99]Kitaoka T, Fukada T, Hibi M, Hirano T. A central role for tat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996,15:3651-3658
[100]Miki S, Iwano M, Miki Y, etal, Interleukin-6 (IL-6) functionsas an invitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989; 250:607-610
[101]Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57:141-146
[102]余寿益 田华琴 黄志庆等,肺癌患者血清sIL-R2、IL-6和TNF-α水平的测定及其临床意义,癌症,2002,19(10)：945
[103]匡弢 王秀美 曹志红,肺癌患者血清sIL-2R、sIL-6R和TNF-α水平变化及意义,山东医药,2004年,第44卷第7期：50
[104]李国玲 邓星奇 王喜英,肺癌患者血清白细胞介素6、可溶性白细胞介素6受体的测定及其临床意义,实用医学杂志,2009年,第25卷第8期：1246-1247
[105]Yanagawa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer.1995 May;71 (5):1095-1098
[106]Burger RA, Grosen EA, Ioli GR, etal. Spontaneous release of inter-leukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovrian carcinoma. Interferon Cytokine Research,1995;15 (3):255-260
[107]周欢琴 翁秀妹 叶雄伟,肺癌患者血清VEGF-C、IL-6和TNF-α水平变化的临床观察,全科医学临床与教育,2010年11月,第八卷第6期：665-666
[108]刘铁梅 赵凤芹 朱光泽,肺癌患者血清sIL-2R、IL-6和TNF-α水平的测定及临床意义,吉林大学学报 (医学版),2002年,第28卷第1期：55-56
[109]郑亚兵 马胜林 周卫民等,参附注射液抗Lewis肺癌小鼠癌性恶液质的肺癌小鼠癌性恶液质的实验研究[J],中华中医药杂志,2009,24(3)：380-382.
[110]De Vita F, Orditura M, Auriemma A, et al. Serum levels of interleukin-6 as aprognostic factor in advanced non-small cell lung cancer. Oncol Rep.1998 May-Jun;5(3):649-52
[111]Scott HR, McMillan DC, Crilly A, et al. The relationship between weight loss andinterleukin 6 in non-small-cell lung cancer. Br J Cancer.1996 Jun; 73(12):1560-2
[112]Ohira T, Nishio K, Ohe Y et al. Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. J. Cancer Res. Clin. Oncol,1996, 122,711-715
[113]Ohe Y, Podack E R, Olsen K J, et al. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shorten survival in syngeneic mice. Br. J. Cancer,67,939-944